RZLT · Insider Trading
Rezolute, Inc. Common Stock (NV)
Every open-market purchase and sale reported by RZLT officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-23 | Daron Evans | CFO | G | −8,000 | — |
| 2026-09-03 | Sunil Ratilal Karnawat | Chief Commercial Officer | F | −2,267 | −$10.20K |
| 2026-07-07 | Brian Kenneth Roberts | Chief Medical Officer | F | −3,062 | −$15.28K |
| 2026-07-07 | Nevan C Elam | CEO | F | −8,004 | −$39.94K |
| 2026-07-07 | Daron Evans | CFO | F | −3,062 | −$15.28K |
| 2026-03-04 | Nevan C Elam | CEO | F | −27,618 | −$82.58K |
| 2026-03-04 | Brian Kenneth Roberts | Chief Medical Officer | F | −11,439 | −$34.20K |
| 2026-03-04 | Daron Evans | CFO | F | −11,438 | −$34.20K |
| 2025-12-17 | Brian Kenneth Roberts | Chief Medical Officer | Buy | +28,000 | +$47.60K |
| 2025-12-17 | Wladimir Hogenhuis | Director | Buy | +5,650 | +$9.55K |
| 2025-12-15 | Sunil Ratilal Karnawat | Chief Commercial Officer | Buy | +12,100 | +$19.60K |
| 2025-12-15 | Nevan C Elam | CEO | Buy | +32,000 | +$50.88K |
| 2025-12-15 | Daron Evans | CFO | Buy | +45,000 | +$79.58K |
| 2025-11-21 | Erik Harris | Director | A | +21,000 | — |
| 2025-11-21 | Philippe Fauchet | Director | A | +21,000 | — |
| 2025-11-21 | Gil M Labrucherie | Director | A | +21,000 | — |
| 2025-11-21 | Brian Kenneth Roberts | Chief Medical Officer | A | +123,000 | — |
| 2025-11-21 | Daron Evans | CFO | A | +107,000 | — |
| 2025-11-21 | Nevan C Elam | CEO | A | +317,000 | — |
| 2025-11-21 | Wladimir Hogenhuis | Director | A | +21,000 | — |
| 2025-11-21 | Young-Jin Kim | Director | A | +21,000 | — |
| 2025-11-21 | Nerissa Kreher | Director | A | +21,000 | — |
| 2025-11-21 | Sunil Ratilal Karnawat | Chief Commercial Officer | A | +32,000 | — |
| 2025-08-27 | Sunil Ratilal Karnawat | Chief Commercial Officer | A | +25,000 | — |
| 2025-06-26 | Brian Kenneth Roberts | Chief Medical Officer | Buy | +2,500 | +$10.94K |
| 2025-06-24 | Daron Evans | CFO | Buy | +5,000 | +$20.25K |
| 2025-06-23 | Young-Jin Kim | Director | Buy | +1,230,769 | +$4.00M |
| 2025-06-23 | Nerissa Kreher | Director | Buy | +3,076 | +$10.00K |
| 2025-06-13 | Wladimir Hogenhuis | Director | A | +9,000 | — |
| 2025-06-13 | Nerissa Kreher | Director | A | +9,000 | — |
| 2025-06-13 | Gil M Labrucherie | Director | A | +9,000 | — |
| 2025-06-12 | Philippe Fauchet | Director | A | +9,000 | — |
| 2025-06-12 | Nevan C Elam | CEO | A | +68,000 | — |
| 2025-06-12 | Daron Evans | CFO | A | +26,000 | — |
| 2025-06-12 | Brian Kenneth Roberts | Chief Medical Officer | A | +26,000 | — |
| 2025-06-12 | Young-Jin Kim | Director | A | +9,000 | — |
| 2025-04-01 | Wladimir Hogenhuis | Director | Buy | +6,758 | +$19.73K |
| 2025-03-31 | Nevan C Elam | CEO | Buy | +12,302 | +$35.00K |
| 2025-03-28 | Daron Evans | CFO | Buy | +20,000 | +$57.70K |
| 2025-03-26 | Erik Harris | Director | A | +60,000 deriv. | — |
| 2025-02-20 | Wladimir Hogenhuis | Director | MIXED | +35,500 | +$47.00K |
| 2025-02-20 | Gil M Labrucherie | Director | A | +25,500 | — |
| 2025-02-19 | Philippe Fauchet | Director | A | +25,500 | — |
| 2025-02-19 | Nerissa Kreher | Director | A | +25,500 | — |
| 2025-02-19 | Young-Jin Kim | Director | MIXED | +1,275,500 | +$5.00M |
| 2025-02-19 | Brian Kenneth Roberts | Chief Medical Officer | A | +77,000 | — |
| 2025-02-19 | Nevan C Elam | CEO | A | +204,000 | — |
| 2025-02-19 | Daron Evans | CFO | A | +77,000 | — |
| 2024-12-18 | Daron Evans | CFO | Buy | +10,000 | +$42.90K |
| 2024-12-12 | Daron Evans | CFO | Buy | +9,000 | +$41.40K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Young-Jin Kim | Director | 8,594,336 | $34.81M |
| Nevan C Elam | CEO | 605,497 | $2.45M |
| Daron Evans | CFO | 415,400 | $1.68M |
| Brian Kenneth Roberts | Chief Medical Officer | 309,351 | $1.25M |
| Wladimir Hogenhuis | Director | 119,675 | $484.68K |
| Gil M Labrucherie | Director | 109,072 | $441.74K |
| Sunil Ratilal Karnawat | Chief Commercial Officer | 71,173 | $288.25K |
| Nerissa Kreher | Director | 58,576 | $237.23K |
| Philippe Fauchet | Director | 55,500 | $224.78K |
| Erik Harris | Director | 21,000 | $85.05K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the RZLT quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.